Company / Capital Expenditures
Gossamer Bio, Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$79.0K
FY2025
5-year range
$0 / $1.5M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#171 of 194
Health Care
What the data says
Gossamer Bio, Inc.'s capital expenditures of $79,000 is lower than 88% of companies in the Health Care sector (FY2025). Improved from $0 to $79,000 over the past 2 years.
Based on SEC 10-K filings.
$79,000 in FY2025 with a 5-year CAGR of -44.5%.
Improved from $0 to $79,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -42.2%
- 5-Year CAGR
- -44.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 194This company $79.0K Sector average $117.5M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -44.5%, indicating a declining trend.
- Ranks #171 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -9.62 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $79.0K | - |
| FY2024 | $0 | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $410.0K | -73.5% |
| FY2021 | $1.5M | +2.9% |
| FY2020 | $1.5M | -49.3% |
| FY2019 | $3.0M | -15.0% |
| FY2018 | $3.5M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026